◎ Sugi Atlas

Atlas / Drug / Semaglutide

Semaglutide

drug
On this page

Also known as NN-9535Nn9535OzempicRybelsusSemaglutidaSemaglutide component of cagrisemaSemaglutide component of nn1535 icosemaSemaglutide component of nn1535 laisemaWegovy

Summary

Semaglutide (CHEMBL2108724) is an approved protein (ATC A10BJ06) targeting GLP1R; indicated across 24 conditions including diabetes mellitus and obesity disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: A10BJ06
  • Targets: 1 (GLP1R)
  • Indications: 24 conditions
  • Clinical trials: 451

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108724
NameSemaglutide
TypeProtein
Max phase4
ATCA10BJ06

Also known as: NN-9535, Nn9535, NN9535, Ozempic, Rybelsus, Semaglutida, Semaglutide, Semaglutide component of cagrisema, Semaglutide component of nn1535 icosema, Semaglutide component of nn1535 laisema, Wegovy, SEMAGLUTIDE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
GLP1RGLP-1 receptorAgonist11.210.2%P43220

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glucagon-like peptide 1 receptor.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
GLP1R10.73EC500.02nMCHEMBL_ACT_23221840
GLP1R10.28EC500.05nMCHEMBL_ACT_25940311
GLP1R10.28EC500.05nMCHEMBL_ACT_26005772
GLP1R9.89IC500.13nMCHEMBL_ACT_15713250
GLP1R9.42IC500.38nMCHEMBL_ACT_15713249
GLP1R8.27Kd5.36nMCHEMBL_ACT_29149921
GLP1R7.52IC5030nMCHEMBL_ACT_15713298
GLP1R6.45IC50357nMCHEMBL_ACT_15713297
GLP1R6.36Kd441nMCHEMBL_ACT_24755227

Target pathways

Aggregated over 1 target gene(s): GLP1R.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion1GLP1R
G alpha (s) signalling events1GLP1R
Glucagon-type ligand receptors1GLP1R

Dominant GO biological processes

GO termTargets
cell surface receptor signaling pathway1
adenylate cyclase-activating G protein-coupled receptor signaling pathway1
activation of adenylate cyclase activity1
positive regulation of cytosolic calcium ion concentration1
learning or memory1
regulation of heart contraction1
post-translational protein targeting to membrane, translocation1
negative regulation of blood pressure1
positive regulation of blood pressure1
hormone secretion1
response to psychosocial stress1
signal transduction1
G protein-coupled receptor signaling pathway1
regulation of biological quality1
cellular response to glucagon stimulus1

Indications & clinical

Indications

24 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
diabetes mellitus4MONDO:0005015EFO:0000400
obesity disorder4MONDO:0011122EFO:0001073
type 2 diabetes mellitus4MONDO:0005148MONDO:0005148
metabolic dysfunction-associated steatotic liver disease3MONDO:0013209EFO:0003095
metabolic dysfunction-associated steatohepatitis3MONDO:0007027EFO:1001249
coronary artery disorder3MONDO:0005010EFO:0001645
Alzheimer disease3MONDO:0004975MONDO:0004975
type 1 diabetes mellitus3MONDO:0005147MONDO:0005147
Klinefelter syndrome3MONDO:0006823EFO:1001006
cardiovascular disorder3MONDO:0004995EFO:0000319
nutritional disorder3MONDO:0005137EFO:0001069
pseudotumor cerebri3MONDO:0009468EFO:1001132
major depressive disorder2MONDO:0002009MONDO:0002009
asthma2MONDO:0004979MONDO:0004979
Parkinson disease2MONDO:0005180MONDO:0005180
diabetic kidney disease2MONDO:0005016EFO:0000401
polycystic ovary syndrome2MONDO:0008487EFO:0000660
nicotine dependence2MONDO:0008575EFO:0003768
alcohol abuse2MONDO:0002046MONDO:0007079
liver disorder2MONDO:0005154EFO:0001421
drug dependence2MONDO:0005303EFO:0003890

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 451.

Phase distribution

PhaseTrials
PHASE3124
PHASE189
Not specified89
PHASE277
PHASE465
PHASE2/PHASE33
PHASE1/PHASE23
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04639414PHASE4ACTIVE_NOT_RECRUITINGCombined Active Treatment in Type 2 Diabetes with NASH
NCT04892199PHASE4ACTIVE_NOT_RECRUITINGDoes GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT05119179PHASE4RECRUITINGPharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
NCT05195944PHASE4ENROLLING_BY_INVITATIONSemaglutide vs Sitagliptin
NCT05441267PHASE4RECRUITINGA Study of Cardiovascular Events iN Diabetes Plus
NCT05780905PHASE4RECRUITINGEffects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
NCT06003153PHASE4RECRUITINGGLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
NCT06042153PHASE4ACTIVE_NOT_RECRUITINGDIALYSIS-TIR Study
NCT06184633PHASE4RECRUITINGDUTCH Weight Control in Atrial Fibrillation Study
NCT06287307PHASE4NOT_YET_RECRUITINGSemaglutide 2.4mg for Low Responders After Bariatric Surgery
NCT06396416PHASE4RECRUITINGObesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
NCT06410352PHASE4RECRUITINGEffectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
NCT06557811PHASE4NOT_YET_RECRUITINGEffect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction
NCT06571383PHASE4ACTIVE_NOT_RECRUITINGSTEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06613854PHASE4RECRUITINGEffect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
NCT06792422PHASE4RECRUITINGA Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma
NCT06801015PHASE4ACTIVE_NOT_RECRUITINGEffects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
NCT06803888PHASE4ACTIVE_NOT_RECRUITINGBariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06814938PHASE4RECRUITINGA Study of a Novel Precision Medicine Approach For Obesity
NCT06851962PHASE4ACTIVE_NOT_RECRUITINGImpact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT06863363PHASE4NOT_YET_RECRUITINGPEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults
NCT06954090PHASE4ENROLLING_BY_INVITATIONUrinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
NCT06959784PHASE4ENROLLING_BY_INVITATIONAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06977438PHASE4NOT_YET_RECRUITINGPromoting Healthy Children and Youth
NCT06986993PHASE4RECRUITINGImpact of Semaglutide on Tobacco Use and Related Health Behaviors
NCT07073053PHASE4NOT_YET_RECRUITINGThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
NCT07213466PHASE4RECRUITINGIndividualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
NCT07239570PHASE4RECRUITINGA Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07242534PHASE4RECRUITINGEffect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
NCT07251556PHASE4NOT_YET_RECRUITINGGLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
NCT07272343PHASE4RECRUITINGThe Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
NCT07275697PHASE4NOT_YET_RECRUITINGWaiting on Atrial Fibrillation Intervention Therapy (WAIT) Study
NCT07314684PHASE4RECRUITINGGLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
NCT07389941PHASE4NOT_YET_RECRUITINGSemaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
NCT07401992PHASE4RECRUITINGEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
NCT07483801PHASE4NOT_YET_RECRUITINGDECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
NCT07485062PHASE4NOT_YET_RECRUITINGExercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
NCT07547878PHASE4NOT_YET_RECRUITINGRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
NCT07554417PHASE4NOT_YET_RECRUITINGCombatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
NCT07592546PHASE4NOT_YET_RECRUITINGTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

17 molecules share ≥1 primary target. Top 17 by shared-target count:

MoleculeSourceStatusShared targets
LIRAGLUTIDEChEMBL + PubChemPhase 4 (approved)GLP1R
DIHYDROERGOTAMINEChEMBLPhase 4 (approved)GLP1R
ELAGOLIXChEMBLPhase 4 (approved)GLP1R
EXENATIDEChEMBLPhase 4 (approved)GLP1R
GLUCAGONChEMBLPhase 4 (approved)GLP1R
LOPERAMIDEChEMBLPhase 4 (approved)GLP1R
PERPHENAZINEChEMBLPhase 4 (approved)GLP1R
SECRETINChEMBLPhase 4 (approved)GLP1R
TIRZEPATIDEChEMBLPhase 4 (approved)GLP1R
TOLVAPTANChEMBLPhase 4 (approved)GLP1R
ORFORGLIPRONChEMBLPhase 3GLP1R
COTADUTIDEChEMBLPhase 2GLP1R
DANUGLIPRONChEMBLPhase 2GLP1R
DEVAZEPIDEChEMBLPhase 2GLP1R
GLP-1ChEMBLPhase 2GLP1R
LOTIGLIPRONChEMBLPhase 2GLP1R
PF-06291874ChEMBLPhase 2GLP1R

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot